Mission Produce, Inc. ( NASDAQ:AVO ) reported results for the second quarter of fiscal 2025 on June 5, 2025, delivering record revenue of $380.3 million, up 28% year-over-year, but lower adjusted EBITDA of $19.1 million.

Albemarle's ALB short percent of float has risen 10.43% since its last report. The company recently reported that it has 18.83 million shares sold short, which is 24.14% of all regular shares that are available for trading.

New York-based cryptocurrency exchange Gemini said Friday that it had filed the paperwork with the SEC to go public.

Lululemon Athletica ( NASDAQ:LULU ) reported its fiscal 2025 first-quarter results on June 5, 2025, delivering revenue growth of 7.3% to $2.4 billion, GAAP EPS of $2.60, and gross margin expanded to 58.3%. Management maintained full-year revenue guidance of $11.15 billion-$11.3 billion ( 7%-8% ...

Here's our initial take on DocuSign's ( NASDAQ: DOCU ) financial report.There was a lot to like about DocuSign's latest quarter. Revenue and adjusted earnings per share were up 8% and 10%, respectively, topping Wall Street expectations.

DocuSign ( NASDAQ:DOCU ) reported Q1 FY2026 results on June 5, with revenue totaling $764 million, up 8% year-over-year, and non-GAAP operating margin climbing to 29.5%. The quarter was defined by rapid adoption of its Intelligent Agreement Management ( IAM ) software, a shift in sales incentives ...

BALA CYNWYD, Pa., June 06, 2025 ( GLOBE NEWSWIRE ) -- Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Provident Bancorp, Inc. ( "Provident" or the "Company" ) ( Nasdaq - PVBC ) for possible breaches of fiduciary duty and other ...

G-III posted Q1 EPS of $0.19 vs $0.12 est. and revenue of $583.6M, driven by strong DKNY, Karl Lagerfeld, and Donna Karan sales. FY26 profit guidance withdrawn due to tariff uncertainty; Q2 revenue forecast of $570M trails $621M Street estimate.

Goldman Sachs sets $24 price target on Teva, citing branded growth and biosimilar pipeline. Amneal gets Buy rating with $12 target as Goldman lauds Parkinson's launch and generics focus. Ready to turn the market's comeback into steady cash flow? Grab the top 3 stocks to buy right here.

USDC issuer Circle's share price is still climbing on its second trading day as it came within pennies of quadrupling its $31 IPO price.